Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin.
Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, Bibollet-Ruche F, Plenderleith LJ, Peeters M, Geyer M, Sharp PM, Fackler OT, Hahn BH, Kirchhoff F. Kluge SF, et al. Among authors: mack k. Cell Host Microbe. 2014 Nov 12;16(5):639-50. doi: 10.1016/j.chom.2014.10.002. Epub 2014 Nov 12. Cell Host Microbe. 2014. PMID: 25525794 Free PMC article.
Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity.
Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Stürzel CM, Mack K, Reith E, Engelhart S, Ciuffi A, Hornung V, Sauter D, Telenti A, Kirchhoff F. Krapp C, et al. Among authors: mack k. Cell Host Microbe. 2016 Apr 13;19(4):504-14. doi: 10.1016/j.chom.2016.02.019. Epub 2016 Mar 17. Cell Host Microbe. 2016. PMID: 26996307 Free article.
Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn GH, Stürzel CM, Leoz M, Plantier JC, Geyer M, Hahn BH, Kirchhoff F. Mack K, et al. J Virol. 2017 Feb 28;91(6):e02177-16. doi: 10.1128/JVI.02177-16. Print 2017 Mar 15. J Virol. 2017. PMID: 28077643 Free PMC article.
Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses.
McLaren PJ, Gawanbacht A, Pyndiah N, Krapp C, Hotter D, Kluge SF, Götz N, Heilmann J, Mack K, Sauter D, Thompson D, Perreaud J, Rausell A, Munoz M, Ciuffi A, Kirchhoff F, Telenti A. McLaren PJ, et al. Among authors: mack k. Retrovirology. 2015 May 16;12:41. doi: 10.1186/s12977-015-0165-5. Retrovirology. 2015. PMID: 25980612 Free PMC article.
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.
Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B, Zuwala K, Mack K, Olesen R, Hua S, Lichterfeld M, Østergaard L, Denton PW, Tolstrup M, Søgaard OS. Vibholm LK, et al. Among authors: mack k. AIDS. 2019 Jul 1;33(8):1315-1325. doi: 10.1097/QAD.0000000000002213. AIDS. 2019. PMID: 30932955 Clinical Trial.
397 results